Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study

Willemieke P. M. Dijksterhuis, Rob H. A. Verhoeven, Sybren L. Meijer, Marije Slingerland, Nadia Haj Mohammad, Judith de Vos-Geelen, Laurens Beerepoot, Theo van Voorthuizen, Geert-Jan Creemers, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)579-590
Number of pages12
JournalGastric Cancer
Volume23
Issue number4
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Esophageal neoplasms
  • Gastric neoplasms
  • Adenocarcinoma
  • ErbB-2 receptor
  • Drug therapy
  • Trastuzumab
  • CLINICAL-PRACTICE GUIDELINES
  • ADVANCED GASTRIC-CANCER
  • QUALITY-OF-LIFE
  • PROGNOSTIC-FACTOR
  • ESOPHAGEAL
  • DIAGNOSIS
  • IMPACT
  • VOLUME
  • CHEMOTHERAPY
  • TRASTUZUMAB

Cite this

Dijksterhuis, W. P. M., Verhoeven, R. H. A., Meijer, S. L., Slingerland, M., Mohammad, N. H., de Vos-Geelen, J., Beerepoot, L., van Voorthuizen, T., Creemers, G-J., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2020). Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. Gastric Cancer, 23(4), 579-590. https://doi.org/10.1007/s10120-020-01039-7